PuraMed BioScience, Inc. (fka PMBS)

[heads]

PuraMed Bioscience Announces Partnership with Avalanche Creative Services, Inc. to Produce First Commercial Featuring LipiGesic™ M for Migraine Relief

August 12, 2009 09:00 AM Eastern Daylight Time

SCHOFIELD, Wis.--(BUSINESS WIRE)--PuraMed Bioscience (OTC Bulletin Board: PMBS), a pharmaceutical company engaged in the development and marketing of a line of revolutionary, new, non-prescription medicines targeting major consumer health needs including the treatment of migraine headaches, insomnia and tension-type headaches, under the brand name LipiGesic™, announced today that it has entered into a partnership with Avalanche Creative Services, Inc. to produce its first television commercial.

Based in New York City, Avalanche creates advertising and marketing that leads to marketplace movements. Avalanche has successfully created and produced over 100 direct response television commercials for nutritional supplement clients in the past six years that have collectively generated over $300 million worth of revenue. Well-known success stories include multiple projects for such companies as Iceland Health, Nutrition 21, Memo Prove, Avacor, Garden of Life, Scandanavian Clinical Nutrition, Cylapril, Fullbar, Focus Factor, Brazilian Basics and more. Avalanche is currently producing a 60- and 120-second spot for PuraMed that will feature the Company’s migraine product, LipiGesic™ M, with a completion date scheduled for early October 2009, at which point testing will begin. PuraMed seeks to air the commercial nationally.

“Through our partnership with Avalanche, we are creating a sustainable and memorable brand image for LipiGesic™ M that will showcase our non-prescription medication solution,” said PuraMed Bioscience CEO Russell Mitchell. “Our commercial will speak to viewers by showing them how our product fulfills a major need—affordable, readily available and effective relief for migraine headaches.

Mitchell continued, “We are pleased to work with Avalanche, and selected them because of their extensive experience in producing advertisements for companies that manufacture non-prescription drugs and supplements. We are confident that through our first direct-response commercial, we will effectively introduce our product to millions of consumers who will then recognize and seek out the LipiGesic™ brand name.”

About the Company:

PuraMed Bioscience, Inc. engages in the research, development and marketing of non-prescription medicinal and healthcare products. In addition to its leading product LipiGesic™ M, which provides acute relief from migraine headaches; the Company also has plans to launch LipiGesic™ PM that provides a remedy for insomnia and other sleep disorders as well as LipiGesic™ H for common tension headaches. For more information on PuraMed, visit the Company website at www.PuraMedBioscience.com.

Forward Looking Statements:

This news release contains forward-looking statements regarding PuraMed Bioscience and its future business plans, which statements involve known and unknown risks and uncertainties. Such risks and uncertainties may cause actual results and future achievements of PuraMed Bioscience to be materially different than those implied by these forward-looking statements. PuraMed Bioscience has and undertakes no obligation to provide public updates and revisions to these forward-looking statements to reflect any changes in its expectations of future events.

Contacts

For more information, contact:
Russell Mitchell, Chairman and CEO
PuraMed Bioscience
715-359-6373
[e-mail]
Website: www.puramedbioscience.com
or
Investor Relations:
Investor Awareness, Inc.
Tony Schor or James Foy, 847-945-2222
Website: www.investorawareness.com
or
Media Contact:
North Shore Public Relations, Inc.
Renae Placinski, 847-945-4505
[e-mail]
Website: www.northshorepr.com

Permalink: http://www.businesswire.com/news/home/20090812005197/en